|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0019564,
umls-concept:C0036341,
umls-concept:C0070122,
umls-concept:C0170657,
umls-concept:C0205396,
umls-concept:C0392747,
umls-concept:C0443172,
umls-concept:C0681850,
umls-concept:C1550501,
umls-concept:C1706203,
umls-concept:C2349001,
umls-concept:C2697811
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1996-12-17
|
|
pubmed:abstractText |
[3H]paroxetine binding to membrane from hippocampus, obtained at autopsy, from 24 schizophrenic and 24 non-schizophrenic subjects has been measured. The affinity of [3H]paroxetine binding to hippocampal membrane was decreased in subjects with schizophrenia (Kd = 0.50 +/- 0.04 vs. 0.24 +/- 0.02nM; mean +/- S.E.M. p < 0.001) but was not different in schizophrenic subjects who had or had not committed suicide (Kd = 0.50 +/- 0.07 vs. 0.50 +/- 0.04nM). The density of [3H]paroxetine binding sites did not differ between the schizophrenic and non-schizophrenic subjects. For the schizophrenic subjects, there was no relationship between ante-mortem neuroleptic drug treatment and [3H]paroxetine binding to the hippocampal membrane. Finally, this study has shown that neuroleptic drug treatment of rats does not alter [3H]paroxetine binding to the hippocampal membranes. Thus, it would seem that the changes in the affinity of [3H]paroxetine binding to the hippocampus of schizophrenic subjects are not likely to be due to neuroleptic drug treatment but may be involved in the pathology of the illness.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antipsychotic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Carrier Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Haloperidol,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Transport Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Nerve Tissue Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Paroxetine,
http://linkedlifedata.com/resource/pubmed/chemical/SLC6A4 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Serotonin,
http://linkedlifedata.com/resource/pubmed/chemical/Serotonin Plasma Membrane...,
http://linkedlifedata.com/resource/pubmed/chemical/Serotonin Uptake Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Slc6a4 protein, rat,
http://linkedlifedata.com/resource/pubmed/chemical/Tritium
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0300-9564
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
103
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
749-57
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:8836936-Adult,
pubmed-meshheading:8836936-Aged,
pubmed-meshheading:8836936-Aged, 80 and over,
pubmed-meshheading:8836936-Animals,
pubmed-meshheading:8836936-Antipsychotic Agents,
pubmed-meshheading:8836936-Binding, Competitive,
pubmed-meshheading:8836936-Carrier Proteins,
pubmed-meshheading:8836936-Female,
pubmed-meshheading:8836936-Haloperidol,
pubmed-meshheading:8836936-Hippocampus,
pubmed-meshheading:8836936-Humans,
pubmed-meshheading:8836936-Male,
pubmed-meshheading:8836936-Membrane Glycoproteins,
pubmed-meshheading:8836936-Membrane Proteins,
pubmed-meshheading:8836936-Membrane Transport Proteins,
pubmed-meshheading:8836936-Middle Aged,
pubmed-meshheading:8836936-Nerve Tissue Proteins,
pubmed-meshheading:8836936-Paroxetine,
pubmed-meshheading:8836936-Rats,
pubmed-meshheading:8836936-Rats, Sprague-Dawley,
pubmed-meshheading:8836936-Schizophrenia,
pubmed-meshheading:8836936-Serotonin,
pubmed-meshheading:8836936-Serotonin Plasma Membrane Transport Proteins,
pubmed-meshheading:8836936-Serotonin Uptake Inhibitors,
pubmed-meshheading:8836936-Suicide,
pubmed-meshheading:8836936-Tritium
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Changes in the serotonin transporter in the hippocampus of subjects with schizophrenia identified using [3H]paroxetine.
|
|
pubmed:affiliation |
Rebecca L. Cooper Laboratories, Mental Health Research Institute of Victoria, Parkville, Australia.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
